Last reviewed · How we verify
Enfortumab Vedotin-Ejfv
Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4.
Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4. Used for Locally advanced or metastatic urothelial cancer, Locally advanced or metastatic urothelial cancer with disease progression during or following platinum-containing chemotherapy, or within 12 months of receiving previous adjuvant chemotherapy in the neoadjuvant or adjuvant setting.
At a glance
| Generic name | Enfortumab Vedotin-Ejfv |
|---|---|
| Also known as | PADCEV |
| Sponsor | Mirati Therapeutics Inc. |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | Nectin-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to Nectin-4 on the surface of cancer cells, which leads to the internalization and degradation of the cells. This results in the inhibition of tumor growth and the induction of apoptosis.
Approved indications
- Locally advanced or metastatic urothelial cancer
- Locally advanced or metastatic urothelial cancer with disease progression during or following platinum-containing chemotherapy, or within 12 months of receiving previous adjuvant chemotherapy in the neoadjuvant or adjuvant setting
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Muscle spasms
- Weight loss
- Vomiting
- Dysgeusia
- Mucosal inflammation
- Thirst
Key clinical trials
- Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (PHASE1)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) (PHASE2)
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial (PHASE4)
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer (PHASE2)
- Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer (PHASE1)
- Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis (PHASE2)
- Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers (PHASE2)
- Sacituzumab Govitecan Plus EV in Metastatic UC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |